Matous, Jeffrey

Randomized trial of lenalidomide versus observation in smoldering multiple myeloma

Lonial, S., Jacobus, S., Fonseca, R., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A. M., Buadi, F. K., O’Brien, T., et al. (2020) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 908

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 381

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., et al. (2023) · Nature Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 257

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Sklavenitis-Pistofidis, R., Aranha, M. P., Redd, R. A., Baginska, J., Haradhvala, N. J., Hallisey, M., Dutta, A. K., Savell, A., Varmeh, S., Heilpern-Mallory, D., et al. (2022) · Cancer Cell

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 70

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

Lonial, S., Jacobus, S. J., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A., Buadi, F., O'Brien, T. E., Matous, J., et al. (2019) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 28